Adjuvant and first line chemotherapy use for endometrial cancer.

ABSTRACT:

Objective

The objective of this study was to describe patterns of utilization of cytotoxic, hormonal, and immunotherapy in patients with endometrial cancer in the adjuvant setting and at the time of first recurrence.

Methods

We identified patients in the IBM MarketScan database with endometrial cancer who underwent hysterectomy from 2011 to 2019. The use of clinically relevant therapeutic agents and combination regimens was determined in the adjuvant setting and at the time of first recurrence.

Results

A total of 22,632 patients were identified. Of these, 7,147 patients (31.6%) received adjuvant radiation and 4,381 (19.4%) received adjuvant chemotherapy following surgery. Of those who received adjuvant chemotherapy, the most commonly utilized agents were carboplatin (

SUBMITTER: Knisely A 

PROVIDER: S-EPMC9126968 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature